Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E'Ola Appealing $13.3 Mil. Ephedrine Supplement Verdict

This article was originally published in The Tan Sheet

Executive Summary

A $13.3 mil. jury verdict for an Alaska woman who claimed her stroke was caused by ephedrine alkaloid-containing dietary supplements could open the door to new lawsuits against the industry.

You may also be interested in...



E’Ola Ephedrine HCl Product Seized, FDA Complaint Alleges Item To Be Drug

Approximately 140,000 bottles of E'Ola International's AMP II Pro Drops, worth roughly $2.8 mil., were seized by U.S. Marshals Oct. 31

E’Ola Ephedrine HCl Product Seized, FDA Complaint Alleges Item To Be Drug

Approximately 140,000 bottles of E'Ola International's AMP II Pro Drops, worth roughly $2.8 mil., were seized by U.S. Marshals Oct. 31

E’Ola Ephedrine HCl Product Seized, FDA Complaint Alleges Item To Be Drug

Approximately 140,000 bottles of E'Ola International's AMP II Pro Drops, worth roughly $2.8 mil., were seized by U.S. Marshals Oct. 31

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel